|
**Overview**: Creatine Phosphokinase Isoenzyme Electrophoresis Panel**Introduction**: The Creatine Phosphokinase Isoenzyme Electrophoresis Panel is a diagnostic tool designed to assess muscle damage using serum samples. In India, elevated CPK (creatine kinase) with isoenzyme fractionation (CPK-MM muscle, CPK-MB cardiac, CPK-BB brain) differentiates skeletal muscle injury (rhabdomyolysis, muscular dystrophy, statin myopathy), myocardial infarction, or CNS damage. High burden of rhabdomyolysis from trauma, infections, drugs, and muscular dystrophies (DMD prevalence ~1 in 3,500 males). High morbidity from underdiagnosis in rural trauma patients, limited electrophoresis labs, delayed fluid resuscitation leading to AKI or compartment syndrome. Per biochemistry practices aligned with ICMR guidelines, the test employs electrophoresis for isoenzyme separation over 1-2 days with high specificity, valuable for precise tissue source identification. This diagnostic falls under muscle damage screening and targets patients with myalgia, weakness, dark urine, or elevated total CPK, addressing accurate detection to guide supportive care or specific therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable isoenzyme analysis.**Other Names**: CPK Isoenzyme Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Isoenzyme electrophoresis standard; in India, used in critical care and neurology.**Purpose**: The test assesses 4 parameters including CPK-MM and CPK-MB to guide muscle damage evaluation, identify tissue source, inform management.**Test Parameters**: 1. CPK-MM, 2. CPK-MB, 3. CPK-BB, 4. Total CPK.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report muscle pain, weakness, dark urine, or trauma.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on muscle symptoms, trauma, statin use, family dystrophy history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated muscle damage including AKI, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using electrophoresis by trained personnel to ensure sterile technique, avoid hemolysis, and interpret isoenzymes within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or exercise can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Predominant CPK-MM indicates skeletal muscle damage, necessitating specialist input. Other patterns suggest cardiac/CNS involvement.**Specialist Consultation**: Neurologists or critical care specialists should be consulted for management.**Additional Supporting Tests**: Total CPK, renal function, urine myoglobin for confirmation.**Test Limitations**: Less sensitive than immunoassays for MB; comprehensive approach required.**References**: Indian Journal of Critical Care Medicine 2024, Rhabdomyolysis Studies India 2023. |
